Vivek Subbiah, MD, is the chief of early-phase drug development at Sarah Cannon Research Institute.
ESMO Congress Marks 50 Years by Showcasing the Future of Cancer Care: Vivek Subbiah, MD
October 15th 2025Vivek Subbiah, MD, highlights key topics at the 50th European Society for Medical Oncology (ESMO) Congress, including the rise of tumor-agnostic therapies and the use of artificial intelligence (AI) in cancer care.